Novartis shielded from punitive damages in Zometa, Aredia case; Pfizer ad banned in U.K.;

@FiercePharma: Top-read story Tues: Today's need-to-know on the Pfizer-AstraZeneca drama? It's all right here. Article | Follow @FiercePharma

@TracyStaton: Big news that doesn't involve Pfizer or AstraZeneca? Refreshing. First: Forest's new chief, Brent Saunders, will head up Actavis post-buyout. | Follow @TracyStaton

@EricPFierce: Canada orders Biolyse to halt production of injectable drug paclitaxel at a plant in Ontario. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Sanofi steps up meningitis marketing amid lagging Menactra sales. FierceVaccines story | Follow @CarlyHFierce

> A federal judge in North Carolina ruled that punitive damages could not be assessed against Swiss drugmaker Novartis ($NVS) in a case alleging jaw injuries caused by its bone drugs Zometa and Aredia because of a lack of evidence that executives acted improperly. Report (reg. req.)

> U.K. cost watchdog NICE declined to approve Johnson & Johnson's ($JNJ) prostate cancer drug Zytiga for patients who have yet to receive chemotherapy. Story

> While cancer patients in the U.S. may have access to drugs not approved in the U.K., they often are more likely to be bankrupted by paying for them, a former Royal College of General Practitioners said in defending stands taken by NICE. Story

> A generic and three branded drugs from Johnson & Johnson ($JNJ), Forest Laboratories ($FRX) and H. Lundbeck used to treat alcoholism were found to reduce addiction. Story

> India's Dr. Reddy's Laboratories has shuffled top management, saying that it wanted to separate the roles of the chairman, CEO and managing director. Story

> The World Health Organization convened a meeting of experts to assess the international risk posed by the highly infectious and often lethal Middle East Respiratory Syndrome (MERS). Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic poaches GE exec to lead its $1.5B diabetes biz. Report | Follow @FierceMedDev

@VarunSaxena2: Tonix's sublingual formulation for fibromylagia reaches pivotal trial stage. Story | Follow @VarunSaxena2

@MichaelGFierce: Boston College team makes zinc nano-cages for 'smart' cancer drug delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: 3-D printed prosthesis brings more dexterity to 12-year-old orphan in Haiti. More from MedCityNews | Follow @EmilyWFierce

> St. Jude Medical achieves first U.S. implants of its TAVR system. Story

> Medrobotics captures $26M in Series E cash for robotic surgery device. More

> Guided Therapeutics preps for a third shot at FDA approval for its cervical scanner. Article

Biotech News

@FierceBiotech: AstraZeneca adds an immuno-oncology collaboration for its pipeline star. News | Follow @FierceBiotech

@JohnCFierce: Not naming names, but everybody I talk to in the industry believes Pfizer's $AZN takeover is numbers driven, lousy for research. Everyone. | Follow @JohnCFierce

@DamianFierce: In which we learn that $PFE's Read always carries a coin with "Straight Talk" on one side and "Own It" on the other. Bloomberg story | Follow @DamianFierce

@EmilyMFierce: Naturally occurring molecule could treat Type 2 diabetes. ICYMI from FierceBiotech Research | Follow @EmilyMFierce

> J&J scouts for 50 Bay biotechs with new Janssen incubator. News

> PhIII eye drug failure? Not at all, says an optimistic Gene Signal. Story

> FDA breaks silence on biosimilars with long-awaited proposal. Report

> Isis heralds positive PhII diabetes results from leading antisense drug. Article

Drug Delivery News

> Alnylam's hepatitis B therapy shows promise in animal studies. Article

> Boston College team makes zinc nano-cages for 'smart' cancer drug delivery. Story

> North Carolina State researchers 'smuggle' drugs into cancer cells with ATP. Report

> MIT researchers deliver low doses of siRNA to lung endothelial cells. Story

> Nanoparticles weaken and then kill cancer cells with two-drug timed release. More

Diagnostics News

> AC Immune and Piramal Imaging link in Alzheimer's imaging agent development deal. Report

> Cinven reportedly puts French Dx outfit Sebia up for sale. More

> Counsyl, armed with $28M, begins big rollout of BRCA and other predictive genetic tests. Story

> Abbott commits to companion Dx development for a promising Idera drug. Article

> Smartphone app shows promise monitoring voice patterns to predict biopolar episodes. More

Pharma Marketing News

> Surprise success of Insys' opioid painkiller Subsys raises eyebrows, More

> Big Biotech beats Big Pharma with best-selling 2013 drug launches. News

> Top GSK exec faces life in Chinese prison for alleged 'massive bribery network.' Story

> Fresh off a TV ad launch, Eisai plots another 200-rep add to Belviq sales force. Article

> Teva's years of Copaxone brand-building pay off in new formula's launch. More

> Sanofi looks to make a splash with meningitis booster-shot push. Story

And Finally... The Advertising Standards Authority (ASA) in the U.K. told Johnson & Johnson ($JNJ) it must discontinue using an advertisement that suggested drinking its Benecol yogurt drinks can lower cholesterol. Story

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.